The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Envisioning the future of early anticancer drug development
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationStratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,449
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“gov/drugdictionary/?CdrID=37857">panitumumab (Vectabix; Amgen) with best supportive care in EGFR-positive metastatic colorectal cancer (CRC”
Backgroundde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182
Self-citationThatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Cohen, S. J., Punt, C. J. A., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E., Miller, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8923 · Cited by 1,841
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
Ki67 in breast cancer: prognostic and predictive potential
Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70262-1 · Cited by 1,207
Talpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,019
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Self-citationHigh-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988
Sawyers, C. L. (2008) · Nature · doi:10.1038/nature06913 · Cited by 983
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Self-citationDose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
Maximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
Dynamic modularity in protein interaction networks predicts breast cancer outcome
Taylor, I. W., Linding, R., Warde-Farley, D., Liu, Y., Pesquita, C., Faria, D., Bull, S., Pawson, T., Morris, Q., & Wrana, J. L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1522 · Cited by 697
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
Self-citationAttard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H. M., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3667 · Cited by 533
Beyond chemotherapy: targeted therapies in ovarian cancer
Yap, T. A., Carden, C. P., & Kaye, S. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2583 · Cited by 495
Self-citationBanerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 488
Self-citationMandrekar, S. J., & Sargent, D. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3701 · Cited by 404
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Self-citationYap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7278 · Cited by 349
Self-citationEconomics of New Oncology Drug Development
DiMasi, J. A., & Grabowski, H. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0803 · Cited by 348
Hostein, I., Robertson, D. M., Di-Stefano, F., Workman, P., & Clarke, P. A. (2001) · PubMed · Cited by 320
Self-citationVan Cutsem, E., Nowacki, M., Lang, I., Cascinu, S., Shchepotin, I., Maurel, J., Rougier, P., Cunningham, D., Nippgen, J., & Köhne, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4000 · Cited by 313
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Jänne, P. A., Gray, N., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303
A network view of disease and compound screening
Schadt, E. E., Friend, S. H., & Shaywitz, D. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2826 · Cited by 291
Raynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 271
Self-citationHaluska, P., Shaw, H. M., Batzel, G. N., Yin, D., Molina, J. R., Molife, L. R., Yap, T. A., Roberts, M. L., Sharma, A., Gualberto, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1118 · Cited by 270
Self-citationDrugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
Workman, P., Clarke, P. A., Raynaud, F. I., & van Montfort, R. L. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4355 · Cited by 264
Self-citationUtilizing RNA interference to enhance cancer drug discovery
Iorns, E., Lord, C. J., Turner, N., & Ashworth, A. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2355 · Cited by 251
Phase I Clinical Trial Design in Cancer Drug Development
Eisenhauer, E. A., O’Dwyer, P. J., Christian, M., & Humphrey, J. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.684 · Cited by 240
Hou, J.-M., Greystoke, A., Lancashire, L., Cummings, J., Ward, T., Board, R., Amir, E., Hughes, S., Krebs, M., Hughes, A., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090078 · Cited by 238
Flaherty, K., Puzanov, I., Sosman, J., Kim, K., Ribas, A., McArthur, G., Lee, R. J., Grippo, J. F., Nolop, K., & Chapman, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9000 · Cited by 229
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
Parulekar, W. R., & Eisenhauer, E. A. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh182 · Cited by 223
Takano, T., Fukui, T., Ohe, Y., Tsuta, K., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Furuta, K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7254 · Cited by 217
Kwak, E. L., Camidge, D. R., Clark, J., Shapiro, G. I., Maki, R. G., Ratain, M. J., Solomon, B., Bang, Y., Ou, S., & Salgia, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3509 · Cited by 207
Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation
Burzykowski, T., & Buyse, M. (2006) · Pharmaceutical Statistics · doi:10.1002/pst.207 · Cited by 200
Clarke, P. A., Hostein, I., Banerji, U., Stefano, F. D., Maloney, A., Walton, M., Judson, I., & Workman, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203753 · Cited by 194
Self-citationWorkman, P., Aboagye, E. O., Chung, Y.-L., Griffiths, J. R., Hart, R., Leach, M. O., Maxwell, R. J., McSheehy, P. M. J., Price, P. M., & Zweit, J. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj162 · Cited by 188
Self-citationDrug development in oncology: classical cytotoxics and molecularly targeted agents
Kummar, S., Gutierrez, M., Doroshow, J. H., & Murgo, A. J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02713.x · Cited by 177
The US Food and Drug Administration perspective on cancer biomarker development
Gutman, S., & Kessler, L. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1911 · Cited by 176
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
Tutt, A., Robson, M., Garber, J. E., Domchek, S., Audeh, M. W., Weitzel, J. N., Friedlander, M., & Carmichael, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra501 · Cited by 174
Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development
Tan, D. S. W., Thomas, G. V., Garrett, M. D., Banerji, U., de Bono, J. S., Kaye, S. B., & Workman, P. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181bd0445 · Cited by 171
Self-citationThe Use of Genomics in Clinical Trial Design
Simon, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4531 · Cited by 170
Attard, G., Reid, A. H. M., Olmos, D., & de Bono, J. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4531 · Cited by 168
Self-citationIasonos, A., Wilton, A. S., Riedel, E. R., Seshan, V. E., & Spriggs, D. R. (2008) · Clinical Trials · doi:10.1177/1740774508096474 · Cited by 166
Banerji, U., Walton, M., Raynaud, F., Grimshaw, R., Kelland, L., Valenti, M., Judson, I., & Workman, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0518 · Cited by 164
Self-citationPharmacodynamic Biomarkers for Molecular Cancer Therapeutics
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 161
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Park, J. W., Kerbel, R. S., Kelloff, G. J., Barrett, J. C., Chabner, B. A., Parkinson, D. R., Peck, J., Ruddon, R. W., Sigman, C. C., & Slamon, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0785 · Cited by 159
Seymour, L., Ivy, S. P., Sargent, D., Spriggs, D., Baker, L., Rubinstein, L., Ratain, M. J., Le Blanc, M., Stewart, D., Crowley, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3287 · Cited by 158
Pharmacogenetics and pharmacogenomics of anticancer agents
Huang, R. S., & Ratain, M. J. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20002 · Cited by 155
A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment
Taube, S. E., Clark, G. M., Dancey, J. E., McShane, L. M., Sigman, C. C., & Gutman, S. I. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp334 · Cited by 153
Workman, P. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033455279 · Cited by 150
Self-citationDevelopment trends for new cancer therapeutics and vaccines
Reichert, J. M., & Wenger, J. B. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.09.003 · Cited by 143
Rubinstein, L., Crowley, J. J., Ivy, P. S., LeBlanc, M. L., & Sargent, D. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2031 · Cited by 140
Optimising the design of phase II oncology trials: The importance of randomisation
Ratain, M. J., & Sargent, D. J. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.029 · Cited by 139
McDermott, U., & Settleman, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9054 · Cited by 131
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
Tutt, A. N. J., Robson, M. E., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M. L., & Carmichael, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.cra501 · Cited by 120
Trends in the Use and Role of Biomarkers in Phase I Oncology Trials
Goulart, B. H. L., Clark, J. W., Pien, H. H., Roberts, T. G., Finkelstein, S. N., & Chabner, B. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2860 · Cited by 111
Targeting CYP17: established and novel approaches in prostate cancer
Yap, T. A., Carden, C. P., Attard, G., & Bono, J. S. D. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.004 · Cited by 110
Self-citationAudeh, M. W., Penson, R. T., Friedlander, M. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.5500 · Cited by 107
Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials
Tang, H. J., Foster, N. R., Grothey, A., Ansell, S. M., Goldberg, R. M., & Sargent, D. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5489 · Cited by 106
Workman, P. (2003) · PubMed · Cited by 105
Self-citationBooth, C. M., Calvert, H., Giaccone, G., Lobbezoo, M. W., Seymour, L., & Eisenhauer, E. A. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.07.034 · Cited by 102
What Is the Right Dose? The Elusive Optimal Biologic Dose in Phase I Clinical Trials
Adjei, A. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4658 · Cited by 100
New science-based endpoints to accelerate oncology drug development
Kelloff, G. J., & Sigman, C. C. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.12.006 · Cited by 89
Randomized Phase III Clinical Trial Designs for Targeted Agents
Hoering, A., LeBlanc, M., & Crowley, J. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0288 · Cited by 89
Nl, S., Blackwell, K., Hurley, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.502 · Cited by 79
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma
Guillard, S., Clarke, P. A., Poele, R. T., Mohri, Z., Bjerke, L. M., Valenti, M. R., Raynaud, F. I., Eccles, S. A., & Workman, P. (2009) · Cell Cycle · doi:10.4161/cc.8.3.7643 · Cited by 77
Self-citationMaximum tolerated dose: clinical endpoint for a bygone era?
Takimoto, C. H. M. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0108-y · Cited by 72
Dose Selection in Phase I Studies: Why We Should Always Go for the Top
Sleijfer, S., & Wiemer, E. A. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5192 · Cited by 71
Biomarkers in Phase I Oncology Trials: Signal, Noise, or Expensive Distraction?
Ratain, M. J., & Glassman, R. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2133 · Cited by 71
Wagner, A. J., Hoff, D., LoRusso, P. M., Tibes, R., Mazina, K. E., Ware, J. A., Yan, Y., Derynck, M. K., & Demetri, G. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3501 · Cited by 66
Challenges of PK/PD measurements in modern drug development
Workman, P. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00395-7 · Cited by 65
Self-citationVogel, C. L., Burris, H. A., Limentani, S. A., Borson, R. A., O’Shaughnessy, J., Vukelja, S. J., Agresta, S., Klencke, B. J., Birkner, M., & Rugo, H. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.1017 · Cited by 63
Relevance of multidrug resistance in the age of targeted therapy.
Türk, D., & Szakács, G. (2009) · PubMed · Cited by 52
Telomerase as a Target for Cancer Immunotherapy
Nguyen, B., Elmore, L. W., & Holt, S. E. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.2.255 · Cited by 48
Targeting the HGF/c-Met Axis: State of Play
Yap, T. A., & Bono, J. S. D. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0122 · Cited by 44
Self-citationChallenges and Pitfalls of Combining Targeted Agents in Phase I Studies
Cannistra, S. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2676 · Cited by 40
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients
Walko, C. M., & McLeod, H. L. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/ncponc1303 · Cited by 40
Sarker, D., Kristeleit, R. S., Mazina, K. E., Ware, J. A., Yan, Y., Dresser, M. J., Derynck, M. K., & De-Bono, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3538 · Cited by 38
Self-citationUse of Pharmacokinetic/Pharmacodynamic Biomarkers to Support Rational Cancer Drug Development
Sarker, D., Pacey, S., & Workman, P. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.3.399 · Cited by 34
Self-citationCirculating tumour-derived predictive biomarkers in oncology
Hodgson, D., Wellings, R. P., Orr, M. C. M., McCormack, R., Malone, M. D., Ruth E. Board, & Cantarini, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.12.006 · Cited by 30
Cited by
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Self-citationImaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Self-citationPharmacological modulation of autophagy: therapeutic potential and persisting obstacles
Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R., & Kroemer, G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.22 · Cited by 842
A decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
“A first-in-human clinical trial of KU-0059436 (KuDOS Pharmaceuticals/ AstraZeneca, later named AZD-2281/olaparib) was conducted to establish a recommended dose and to generate preliminary data in a biomarker-defined population [6, 7].”
Method
Metadata
- Authors
- Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S.
- Venue
- Nature Reviews Cancer
- Published
- 2010-06-10
- Volume
- 10
- Issue
- 7
- Pages
- 514-523
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2103146352
- Cited by
- 281
- References
- 98
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.